-transparent.png){kind=logo}
GABAB receptor agonist baclofen improves methamphetamine-induced cognitive deficit in mice. 2009
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
Laboratory of Neuropsychopharmacology, Division of Life Sciences, Graduate School of Natural Science and Technology, Kanazawa University, Kanazawa 920-1192, Japan.
In this study, we investigated the effects of GABA(A) and GABA(B) receptor agonists on the methamphetamine-induced impairment of recognition memory in mice. Repeated treatment with methamphetamine at a dose of 1 mg/kg for 7 days induced an impairment of recognition memory. Baclofen, a GABA(B) receptor agonist, ameliorated the repeated methamphetamine-induced cognitive impairment, although gaboxadol, a GABA(A) receptor agonist, had no significant effect. GABA(B) receptors may constitute a putative new target in treating cognitive deficits in patients suffering from schizophrenia, as well as methamphetamine psychosis.
Related Publications
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
January 1990,
Archives internationales de pharmacodynamie et de therapie,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
December 2022,
Glia,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
March 2011,
Current neuropharmacology,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
June 2007,
Neuropharmacology,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
May 2003,
European journal of pharmacology,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
January 2012,
European journal of pharmacology,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
February 1996,
Pharmacology, biochemistry, and behavior,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
January 2014,
Biochemical and biophysical research communications,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
July 2013,
Neuropharmacology,
Sawako Arai, and
Kazuhiro Takuma, and
Hiroyuki Mizoguchi, and
Daisuke Ibi, and
Taku Nagai, and
Hiroyuki Kamei, and
Hyoung-Chun Kim, and
Kiyofumi Yamada
November 1995,
Neuroscience,
